Martin Petkov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Martin Petkov has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Schmidt
Biozentrum, University of Basel
1 shared publication - Ashik Ahmed Abdul Pari
European Center for Angioscience, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany 1
1 shared publication - Benjamin Schieb
European Center for Angioscience, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany 1
1 shared publication - Christian Moritz Heyer
University of Augsburg
1 shared publication - Christoph Reissfelder
Department of Surgery, Medical Faculty Mannheim, Universitätsmedizin Mannheim, Heidelberg University, Mannheim, Germany
1 shared publication - Claudine Fricke
European Center for Angioscience, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany 1
1 shared publication
Latest Publications
- Open Access
- 21 October 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 220 (1)
Primary tumor–derived systemic nANGPTL4 inhibits metastasis
Primary tumors and distant site metastases form a bidirectionally communicating system. Yet, the molecular mechanisms of this crosstalk are poorly understood. Here, we identified the proteolytically cleaved fragments of angiopoietin-like 4 (ANGPTL4) as contextually active protumorigenic and antitumorigenic contributors in this communication ecosystem. Preclinical studies in multiple tumor models revealed that the C-terminal fragment (cANGPTL4) promoted tumor growth and metastasis. In contrast, the N-terminal fragment of ANGPTL4 (nANGPTL4) inhibited metastasis and enhanced overall survival in a postsurgical metastasis model by inhibiting WNT signaling and reducing vascularity at the metastatic site. Tracing ANGPTL4 and its fragments in tumor patients detected full-length ANGPTL4 primarily in tumor tissues, whereas nANGPTL4 predominated in systemic circulation and correlated inversely with disease progression. The study highlights the spatial context of the proteolytic cleavage-dependent pro- and antitumorigenic functions of ANGPTL4 and identifies and validates nANGPTL4 as a novel biomarker of tumor progression and antimetastatic therapeutic agent.
- 21 October 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 220 (1)
Open AccessPrimary tumor–derived systemic nANGPTL4 inhibits metastasis
Primary tumors and distant site metastases form a bidirectionally communicating system. Yet, the molecular mechanisms of this crosstalk are poorly understood. Here, we identified the proteolytically cleaved fragments of angiopoietin-like 4 (ANGPTL4) as contextually active protumorigenic and antitumorigenic contributors in this communication ecosystem. Preclinical studies in multiple tumor models revealed that the C-terminal fragment (cANGPTL4) promoted tumor growth and metastasis. In contrast, the N-terminal fragment of ANGPTL4 (nANGPTL4) inhibited metastasis and enhanced overall survival in a postsurgical metastasis model by inhibiting WNT signaling and reducing vascularity at the metastatic site. Tracing ANGPTL4 and its fragments in tumor patients detected full-length ANGPTL4 primarily in tumor tissues, whereas nANGPTL4 predominated in systemic circulation and correlated inversely with disease progression. The study highlights the spatial context of the proteolytic cleavage-dependent pro- and antitumorigenic functions of ANGPTL4 and identifies and validates nANGPTL4 as a novel biomarker of tumor progression and antimetastatic therapeutic agent.